Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.75 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948404 | 0.88 | CYP4F2 (0.73) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1859513 | 0.86 | CYP4F2 (0.78) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL22098221 | 0.86 | CYP4F2 (1.00) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL13948679 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL27567553 | 0.84 | CYP4F2 (0.71) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL16673195 | 0.84 | CYP4F2 (0.55) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL12179901 | 0.83 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL11911407 | 0.83 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9713399 | 0.83 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1207466 | 0.83 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | CYP4F2 494/4885CYP4A11 109/4885SMN1; SMN2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.